PCVX (Vaxcyte) Tariff Resilience Score: 6/10 (As of Jun. 29, 2026)


PCVX Vaxcyte Inc PCVX
35 GF Score
Price $57.66
! 3 Warning Signs
View Full Analysis

What is Vaxcyte Tariff Resilience Score?

Vaxcyte PCVX +2.12% 35 Tariff Resilience Score is 6 as of Jun. 29, 2026. GuruFocus rates PCVX with a GF Score™ of 35/100. The stock has 3 warning signs investors should review. Among 1,375 Biotechnology companies, Vaxcyte ranks better than 76% on this metric.

Vaxcyte has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Vaxcyte has Vaxcyte's reliance on international suppliers for vaccine components exposes it to tariffs. However, its focus on critical healthcare products and potential for alternative sourcing provide moderate resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Vaxcyte might have Average Resilient.

Vaxcyte  (NAS:PCVX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Vaxcyte Tariff Resilience Score Related Terms

PCVX vs IMVT, PTGX, TGTX: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Vaxcyte's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vaxcyte Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxcyte's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Vaxcyte's Tariff Resilience Score falls into.


PCVX
35GF Score
Vaxcyte Inc PCVX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Vaxcyte (PCVX) has a Tariff Resilience Score of 6 as of Jun. 29, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Vaxcyte ranks #330 out of 1375 companies in the Biotechnology industry, placing it in the top 24%.
Is Vaxcyte's Tariff Resilience Score too high?
Vaxcyte's current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Vaxcyte's value of 6 is 50% above this industry median. Based on the distribution chart, Vaxcyte ranks #330 out of 1375 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vaxcyte has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Vaxcyte's Tariff Resilience Score compare to IMVT and PTGX?
According to the Biotechnology industry distribution chart, Vaxcyte ranks #330 out of 1375 companies for Tariff Resilience Score. This places Vaxcyte in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Vaxcyte's value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,375 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vaxcyte's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vaxcyte's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxcyte stock overvalued right now?
Vaxcyte (PCVX) has a current Tariff Resilience Score of 6. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Vaxcyte's overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Vaxcyte (PCVX), the current Tariff Resilience Score is 6 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vaxcyte Business Description

Other Exchanges 1PCVX:Italy5VA:Germany
Address 825 Industrial Road, Suite 300, San Carlos, CA, USA, 94070
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
35GF Score

Get the complete analysis for PCVX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$57.66
Price